Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk ER-Positive HER2-Negative DCIS
NCT07762885Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ductal carcinoma in situ (DCIS) (2 arms), sponsored by Fudan University. Primary endpoint: Ipsilateral Breast Tumor Recurrence at 5 years. Started Jul 2026; status: recruiting.
02
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT07762885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762885.